Anti‐PD‐L1 immunotherapy reinvigorates the antitumor CD8+ T cell response for tumor control.[23] We wondered whether the improved antitumor CD8+ T cell response by NK‐specific Tipe2 deletion could further improve the therapeutic efficacy of anti‐PD‐L1 immunotherapy. The gene discussed is TIPE2; the disease is neoplasm.